Nutcracker Therapeutics
- Company typePrivate
- Founded2018
- HeadquartersEmeryville, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Nutcracker Therapeutics firmographics
Firmographics- Name
- Nutcracker Therapeutics
- Website
- https://nutcrackerx.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Nutcracker Therapeutics industry classification
Industry- Product category
- RNA Therapeutics Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
- akta.pro secondary industries
- mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)
Keywords
Where Nutcracker Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Emeryville
- HQ country
- United States
- HQ region
- North America
Markets served
Nutcracker Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- RNA Therapeutic Pipeline Development: Developing proprietary mRNA medicines for cancer applications with the intention of commercializing therapeutic products through clinical development and eventual FDA approval.
- Contract Manufacturing Services: Providing small-batch RNA manufacturing services to pharmaceutical partners using the NMU-Symphony platform for personalized and advanced therapeutic production.
Go-to-market motion2 records
Marketing channels1 record
Nutcracker Therapeutics product offering
Product offeringCore offering
Nutcracker Therapeutics develops and manufactures mRNA-based therapeutics for cancer using a proprietary biochip-based "GMP-in-a-box" manufacturing platform. The company's core offering is the NMU-Symphony system, an automated, self-contained, single-use small RNA manufacturing system that applies semiconductor automation strategies to biopharmaceutical production, enabling cost-effective small-batch and personalized therapeutic manufacturing from patient-specific archived tumors.
Product overview
Nutcracker Therapeutics offers an integrated RNA therapeutics platform centered on its proprietary biochip-based manufacturing technology ('GMP-in-a-box'), which enables rapid, automated production of small-batch RNA medicines. The core product, NMU-Symphony, is an automated self-contained single-use manufacturing system that applies semiconductor manufacturing automation strategies to biopharmaceutical production. The platform supports a pipeline of mRNA medicines for cancer applications, enabling personalized therapeutics from archived tumors. The products function as a unified system where the biochip platform underpins the NMU-Symphony manufacturing system, which in turn enables the company's personalized cancer therapeutic pipeline.
Differentiator
Problem solved
Functional benefit
Brands
- NMU-Symphony: Automated, self-contained, single-use small RNA manufacturing system for cost-effective production of personalized and small-batch advanced therapeutics
Products and services
- NMU-Symphony Automated, self-contained, single-use small RNA manufacturing system designed to enable cost-effective production of personalized and small-batch advanced therapeutics, particularly personalized cancer therapeutics manufactured from patient archived tumors.
- Biochip-based Manufacturing Platform Proprietary push-button RNA manufacturing platform featuring 'GMP-in-a-box' biochips that enable GMP-compliant RNA production in a compact, self-contained format, supporting rapid development of RNA therapeutics.
- RNA Therapeutics Pipeline Pipeline of mRNA medicines targeting various cancers, developed using the company's biochip-based manufacturing technology for small-batch personalized therapeutics.
Quantifiable outcome
- Machine learning improved first-attempt manufacturing success rate from very low to 100% across a batch of 10 patients
- +1 more outcomes
Companies that use Nutcracker Therapeutics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Nutcracker Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Nutcracker Therapeutics partnerships and signals
Strategic signalScale indicators4 records
Recent moves5 records
Expansion highlights5 records
Nutcracker Therapeutics competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks1 record
Key highlights6 records
Customer concentration
Nutcracker Therapeutics social profiles
Digital presenceNutcracker Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nutcracker Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
Nutcracker Therapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nutcracker Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nutcracker Therapeutics
What does Nutcracker Therapeutics do?
Nutcracker Therapeutics develops and manufactures mRNA-based therapeutics for cancer using a proprietary biochip-based "GMP-in-a-box" manufacturing platform. The company's core offering is the NMU-Symphony system, an automated, self-contained, single-use small RNA manufacturing system that applies semiconductor automation strategies to biopharmaceutical production, enabling cost-effective small-batch and personalized therapeutic manufacturing from patient-specific archived tumors.
Is Nutcracker Therapeutics a public or private company?
Nutcracker Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nutcracker Therapeutics founded?
Nutcracker Therapeutics was founded in 2018. It employs 101 to 250 people.
Where is Nutcracker Therapeutics based?
Nutcracker Therapeutics is headquartered in Emeryville, United States, in the North America region.
How does Nutcracker Therapeutics make money?
Two revenue lines are on record. RNA Therapeutic Pipeline Development is the primary driver. The others are contract Manufacturing Services.
Does Nutcracker Therapeutics have an API?
No public API is recorded for Nutcracker Therapeutics.
What industry is Nutcracker Therapeutics in?
Nutcracker Therapeutics's product category is RNA Therapeutics Manufacturing. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA). Its NAICS code is 325414 and its SIC code is 2836.